Biochimpharm Aims to Pioneer Georgian Phage Exports to Europe

The CEO of "Biochimpharm," a leading Georgian phage production company, is optimistic about the future, anticipating that their phages will soon break into European markets. Rati Golijashvili shared his vision, reflecting on the significant milestones the company has achieved to date.

Founded in Tbilisi in 1934, "Biochimpharm" has recently been awarded a GMP (Good Manufacturing Practice) certificate, marking a crucial step towards the European export of their phage products. This certification was a key hurdle for the company's ambitions to penetrate European markets, according to the company's leadership. With this in place, "Biochimpharm" is now navigating the remaining regulatory processes required for direct exports.

Golijashvili highlighted the intricate nature of regulatory standards and procedures in their field, underscoring the importance of adhering to production standards and the specific steps necessary to introduce their unique phages into European markets. With a major barrier now surpassed, the company is actively seeking distribution partners and navigating the registration and marketing authorization processes for their products in Europe.

"We are hopeful and determined that in the near term, 'Biochimpharm' will be at the forefront of exporting phage-based therapies and sterile pharmaceutical forms to Europe," stated Golijashvili, expressing confidence in the company's pioneering journey ahead.